Soleno Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1999-08-25
- Employees
- 42
- Market Cap
- $1.9B
- Website
- http://www.soleno.life
Clinical Trials
6
Active:1
Completed:3
Trial Phases
2 Phases
Phase 2:1
Phase 3:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 3
4 (80.0%)Phase 2
1 (20.0%)Open-Label Extension Study of DCCR in Patients With Prader-Willi Syndrome
- First Posted Date
- 2023-01-27
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Soleno Therapeutics, Inc.
- Target Recruit Count
- 83
- Registration Number
- NCT05701774
- Locations
- 🇺🇸
UC Irvine, Orange, California, United States
🇺🇸Stanford University, Palo Alto, California, United States
🇺🇸Rady Children's Hospital of San Diego, San Diego, California, United States
An Open-Label Study of Diazoxide Choline in Patients With Genetic Obesities
Phase 2
Not yet recruiting
- Conditions
- SH2B1 Deficiency ObesityObesity Associated With PCSK1 Mutation (rs6232 Variant)SIM1 Deficiency Obesity
- Interventions
- Drug: DCCR (diazoxide choline) extended-release tablets
- First Posted Date
- 2022-09-08
- Last Posted Date
- 2022-09-08
- Lead Sponsor
- Soleno Therapeutics, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05532020
PWS Outcomes Assessment Study
Completed
- Conditions
- Prader-Willi Syndrome
- First Posted Date
- 2019-09-25
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Soleno Therapeutics, Inc.
- Target Recruit Count
- 59
- Registration Number
- NCT04102839
- Locations
- 🇺🇸
Casimir Trials, Plymouth, Massachusetts, United States
An Open-Label Study of DCCR Tablet in Patients With PWS
- First Posted Date
- 2019-09-12
- Last Posted Date
- 2021-08-03
- Lead Sponsor
- Soleno Therapeutics, Inc.
- Registration Number
- NCT04086810
Open-Label Extension Study of DCCR in PWS Followed by Double-Blind, Placebo-Controlled, Randomized Withdrawal Period
- First Posted Date
- 2018-10-22
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Soleno Therapeutics, Inc.
- Target Recruit Count
- 115
- Registration Number
- NCT03714373
- Locations
- 🇺🇸
University of California, Irvine, Orange, California, United States
🇺🇸Stanford University, Palo Alto, California, United States
🇺🇸Rady Children's Hospital San Diego, San Diego, California, United States
- Prev
- 1
- 2
- Next
News
No news found